FDA is now “open to bayesian statistics”: transformational change or new Pandora’s box?

The US Food and Drug Administration (FDA) is now “open to bayesian statistics,” contrasting this with the frequentist approach that the agency and the drug industry have historically relied on for statistical analysis.